d
-glucose might be a trigger of endothelial injury. However, the physiological role of the local vascular HGF system has not yet been clarified. To investigate the role of HGF in endothelial injury, we initially examined the effects of HGF on endothelial injury induced by serum deprivation. Decrease in EC number by serum deprivation was significantly attenuated by addition of HGF as well as recombinant basic fibroblast growth factor, whereas vascular endothelial growth factor showed no effect. Apoptotic changes in EC induced by serum deprivation were also significantly attenuated by addition of HGF (p < 0.01). Given the protective action of HGF, we next studied the physiological role of local HGF production in endothelial regulation. We focused on the protective actions of prostaglandin (PG) I 2 , PGE and a phosphodiesterase type 3 inhibitor (cilostazol) on endothelial injury by high glucose, since these agents are widely used in the treatment of peripheral arterial disease which is frequently observed in diabetic patients. Treatment of human aortic EC with PGE 1 , PGE 2 , and a PGI 2 analogue (beraprost sodium) as well as cilostazol stimulated EC growth. HGF concentration in conditioned medium from EC treated with PGE 1 , PGE 2 or PGI 2 analogue as well as cilostazol was significantly higher than that with vehicle (p < 0.01). Interestingly, treatment with PGI 2 analogue or cilostazol attenuated high d -glucose-induced EC death, which was abolished by neutralizing anti-HGF antibody. Moreover, decreased local HGF production by high d -glucose was also significantly attenuated by PGI 2 analogue or cilostazol. Finally, we tested the effects of PGE, PGI 2 analogue and cilostazol on local HGF production in human aortic vascular smooth muscle cells (VSMC). Although high d -glucose treatment resulted in a significant increase in VSMC number, PGI 2 analogue and/or cilostazol treatment had no effects on VSMC growth. However, the decrease in local HGF production by high Endothelial cells are known to secrete various vasoactive substances. Recently, it has been hypothesized that endothelial cells may also modulate vascular growth, because many anti-proliferative factors such as nitric oxide and vascular natriuretic peptides are secreted by endothelial cells [1] [2] [3] . Therefore, it is apparent that dysfunction of endothelial cells may promote abnormal vascular growth such as in atherosclerosis and arteriosclerosis [4, 5] . Our previous studies demonstrated that hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors, whose mitogenic activity is the most potent [6, 7] . Moreover, the presence of a local HGF system (HGF and its receptor, c-met) in endothelial cells and vascular smooth muscle cells (VSMC) was also demonstrated in vitro as well as in vivo [8] . Thus, it is important to know the physiological role of HGF in endothelial regulation, as the loss of anti-proliferative substances from endothelial cells might be related to the development and progression of atherosclerosis/arteriosclerosis in diabetes mellitus (DM) and hypertension. In this study, we initially examined whether HGF has a protective role in endothelial regulation using human cultured aortic endothelial cells.
On the other hand, prostaglandin (PG) I 2 and PGE have been reported to have a cytoprotective action on endothelial cells and to inhibit VSMC growth [9] [10] [11] . PGI 2 and PGE are well known to stimulate cyclic AMP (cAMP) which plays a pivotal role in the regulation of glucose metabolism, platelet aggregation and VSMC relaxation. Cyclic AMP is synthesized from ATP by adenylate cyclase, and converted to 5'-AMP by phosphodiesterase (PDE) [12] . PGI 2 and PGE directly activate adenylate cyclase, resulting in the accumulation of cAMP. One of the ratelimiting steps in the cascade of the cAMP pathway is PDE. Type 3 PDE, which is known as cAMP-PDE and degrades cAMP and is inhibited by cGMP, mainly exists in platelets, VSMC, cardiac myocytes and adipose tissue [12] . Therefore, PDE 3 inhibitors inhibit platelet aggregation and VSMC relaxation through the activation of cAMP [13] [14] [15] . Indeed, these agents, which cause accumulation of cAMP, are widely used for the treatment of peripheral arterial disease observed in diabetes [16] [17] [18] . Diabetes is characterized by the premature development of microvascular and macrovascular disease [19] [20] [21] , and hyperglycaemia is an independent risk factor for the development of cardiovascular disease [22] . Interestingly, high glucose treatment caused endothelial cell death through a decrease in local HGF production [23] . As addition of recombinant HGF prevented the endothelial cell death induced by high glucose [23] , HGF seems to play a pivotal role in the regulation of endothelial cells. Therefore, in this study, we examined the effects of PGE, a stable oral PGI 2 analogue (beraprost sodium) and a PDE 3 inhibitor (cilostazol) on local HGF production in vascular cells, to clarify the potential role of HGF in endothelial injury induced by high d -glucose.
Materials and methods
Cell culture. Human aortic endothelial cells (passage 5) and human aortic VSMC (passage 5) were obtained from Clonetics Corp. (San Diego, Calif., USA), and cultured in modified MCDB131 medium supplemented with 5 % fetal calf serum, 100 IU/ml penicillin, 100 mg/ml streptomycin, 10 ng/ml epidermal growth factor, 2 ng/ml basic fibroblast growth factor (FGF) and 1 m mol/l dexamethasone in the standard fashion [24, 25] . Cells were incubated at 37°C in a humidified atmosphere of 95 % air-5 % CO 2 with medium changes every 2 days. These cells showed the specific characteristics of endothelial cells and VSMC, on immunohistochemical examination and morphological observation. Briefly, human aortic endothelial cells tested positive for factor VIII antigen and for uptake of di-acetylated LDL. In contrast, human aortic VSMC also tested positive for a -actin, and negative for expression of factor VIII antigen. All the cells were used between passage 5-6.
Counting of cell number. An index of cell proliferation was determined using the WST-cell counting kit which is similar to MTT assay (Wako, Osaka, Japan) [23, [26] [27] [28] . Tetrazolium salt has been used to develop a quantitative colorimetric assay for cell growth. The assay detects living, but not dead cells, and the signal generated is dependent on the degree of activation of the cells. For this purpose, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) is widely used [29] . In this study, we used an alternative to MTT, sulfonated tetrazolium salt, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulfonate (WST-1), since this compound produces a highly water-soluble formazan dye, which makes the assay procedure easier to perform [28] . Briefly, 16.3 mg WST-1 and 0.2 mmol/l 1-methoxy-5-methyl-phenazinium methylsulfate were dissolved in 20 mmol/l HEPES buffer (pH 7.4). Then, 10 m l of the reaction solution was immediately added to 100 m l culture medium per well and the cells were then incubated for an additional 2 h. The plate was read on a Bio-Rad Model 3550 Microplate reader, using a test wavelength of 450 nm, and a reference wavelength of 650 nm. We confirmed that serum-stimulated increase in cell number is associated with increased absorbance at 450 nm (data not shown).
Treatment by serum deprivation. In the preparation of experiments for determination of cell death, endothelial cells were grown to confluence. After reaching confluence, the medium was changed to fresh defined serum-free medium containing HGF, basic FGF, vascular endothelial cell growth factor (VEGF), or vehicle. Defined serum-free medium was supplemented with insulin (5 × 10 -7 mol/l), transferrin (5 mg/ml), and ascorbate (0.2 mmol/l), as previously described [30] . The cells were then incubated. Every 2 days, the medium was changed to fresh defined serum-free medium containing HGF, basic FGF, VEGF, or vehicle. On days 2 and 4, an index of cell proliferation was determined, as described above.
Apoptotic cells induced by serum deprivation were also counted at 4 days. Hoechst 33 342 (Sigma, St. Louis, Mo., USA) was used to observe nuclear morphology by fluorescence microscopy under ultraviolet light. It was prepared extemporaneously in distilled water at 1 mg/ml and added to the culture medium at a final concentration of 10 m g/ml [31, 32].
After 2 h of incubation at 37°C, cells were washed twice in phosphate buffered saline and resuspended at a concentration of 10 6 cells/ml in phosphate buffered saline containing 1 % (w/ v) paraformaldehyde. Cell deposits of approximately 40 000 cells were applied to glass slides. After staining with Hoechst 33342, the morphological features of cell nuclei were observed with an epifluorescence microscope. For each sample, 300 cells were examined. The number of apoptotic cells was counted under microscopy (magnification, × 100) in a blinded manner. The total number of apoptotic cells in each section was summed and expressed as a percentage of total cell number. At least ten individual sections were evaluated per slide. Samples were coded so that the analysis was performed without knowledge of which treatment each cells had received. The reproducibility of the results was assessed. Intraobserver variability was determined from triplicate measurements performed by one observer for all sections. The mean ± SD difference among measurements made by the same observer was 2.4 ± 0.3 %. Interobserver variability was determined from measurements of ten randomly selected sections performed by a second observer in addition to the first observer. The difference between measurements made by the two observers was 3.4 ± 0.5 %. These observers were blinded to other data concerning the cells, as well as to the results of the other observer.
Treatment with prostaglandins and cilostazol. Endothelial cells and VSMC were seeded onto uncoated 96-well tissue culture plates (Corning, N. Y., USA). In the preparation of experiments for determination of cell count, the cells were grown to sub-confluence. After cells reached 80 % confluence, the medium was changed to fresh defined serum-free medium for VSMC or endothelial cells, containing PGE, PGI 2 , cilostazol or vehicle, both with and without high glucose (5 to 25 mmol/ l). The cells were then incubated overnight. On day 1, the medium was again changed to fresh medium with normal or high d -glucose. On day 4, an index of cell proliferation was determined using a WST-cell counting kit, as described above.
Measurement of HGF in conditioned medium.
Human endothelial cells and VSMC were seeded on 6-well plates (Corning) at a density of 5 × 10 4 cells/cm 2 and cultured for 48 h. After replacing the medium with fresh defined serum-free medium and following culture for 48 h, the concentration of HGF in the medium was determined by enzyme-immunoassay using anti-human HGF antibodies, as described previously [33] . Rabbit anti-human HGF IgG was coated on a 96-well plate (Corning) at 4°C for 15. After blocking with 3 % bovine serum albumin in phosphate-buffered saline phosphate buffered saline, conditioned medium was added to each well, and the preparation was incubated for 2 h at 25°C. Wells were washed three times with PBS containing 0.025 % Tween 20 (PBS-Tween), then biotinylated rabbit anti-human HGF IgG was added and the preparation was incubated for 2 h at 25°C. After washing with PBSTween, wells were incubated with horseradish peroxidase-conjugated streptoavidin-biotin complex in PBS-Tween. The enzyme reaction was initiated by adding substrate solution composed of 2.5 mg/ml o-phenylenediamine, 100 mmol/l sodium phosphate, 50 mmol/l citric acid, and 0.015 % H 2 O 2 . The enzyme reaction was halted by adding 1 mol/l H 2 SO 4 , and absorbance at 490 nm was measured. This ELISA specifically detects human HGF, but not rat HGF [33] .
Effect of neutralizing anti-HGF antibody.
The effect of endogenously produced HGF in human endothelial cells and VSMC was examined by a neutralization procedure, using rabbit anti-human HGF antibody [34] . For the antibody, the IgG fraction (purified with protein A-agarose) was able to neutralize a biological activity of 10 ng/ml HGF, at a concentration of 10 Materials. Human recombinant HGF was purified from the culture medium of Chinese hamster ovary cells or C-127 cells, and transfected with expression plasmid containing human HGF cDNA [35, 36] . PGE 1 and PGE 2 were obtained from Sigma. PGI 2 analogue (beraprost sodium) was donated by Kaken Pharmaceutical Company (Tokyo, Japan). Cilostazol was donated by Otsuka Pharmaceutical Company (Osaka, Japan).
Statistical analysis. All values are expressed as mean ± SEM. Analysis of variance with subsequent Bonferroni's/Dunnet test was employed to determine the significance of differences in multiple comparisons. Values of p < 0.05 were considered statistically significant.
Results
Effect of HGF on endothelial cell death induced by serum deprivation. Initially, we examined the effect of HGF treatment on cell death induced by serum deprivation. Serum deprivation caused endothelial cell death. Some cells started to become round and eventually detached from the plate and floated in the medium 4 h after serum deprivation, leaving many holes in the sheet of confluent cells. The floating cells could be recovered with the medium, and neither attached onto a new plate nor proliferated (data not shown). Consistent with this morphological observation, cell death rate after serum deprivation was significantly increased in a time-dependent manner, as shown in Figure 1 . Addition of HGF (10 ng/ml) or FGF (10 ng/ml) resulted in partial attenuation of cell death mediated by serum deprivation. Moreover, co-incubation with HGF and bFGF completely abolished endothelial cell death, similar to serum (10 % fetal calf serum) treatment. Moreover, addition of VEGF (10 ng/ml) to HGF and bFGF had no additive effect on survival rate of endothelial cells (data not shown). Serum deprivation resulted in a significant increase in apoptotic endothelial cells assessed by morphology, as shown in Figure 2 a. Serum deprivation significantly increased the apoptotic cells, which was abolished by the addition of serum (p < 0.01). Importantly, addition of recombinant HGF also prevented apoptosis of endothelial cells induced by serum deprivation (Fig. 2 b) . These results were also confirmed by nuclear staining using propidium iodide (data not shown). (Fig. 3 a) . DNA synthesis of endothelial cells was also increased by PGI 2 analogue (data not shown). As mentioned earlier, HGF is a novel endothelium-specific growth factor. Therefore, we studied the role of local HGF production in prostaglandintreated endothelial cells. Treatment with PGE 1 , or (Fig. 3 b) . Therefore, we hypothesized that PGE and PGI 2 analogue improved endothelial dysfunction through stimulation of local HGF production. To test this hypothesis, we studied the effect of prostaglandins on endothelial cell death induced by high d -glucose. As shown in Figure 4 , treatment with high d -glucose (25 mmol/l) resulted in a significant decrease in endothelial cell number, whereas addition of PGI 2 analogue attenuated endothelial cell death induced by high d -glucose. Of importance, the prevention of endothelial cell death by PGI 2 analogue was significantly abolished by addition of neutralizing anti-HGF antibody. As previously reported, no significant changes were observed in cell number of endothelial cells treated with high mannitol or L-glucose [23] .
Local HGF secretion of endothelial cells treated with cilostazol was also examined, since cilostazol is also used in the treatment of peripheral arterial disease. As shown in Figure 5 a, treatment with cilostazol significantly stimulated local HGF production in human aortic endothelial cells under basal conditions. The stimulatory action of PGE, a PGI 2 analogue and cilostazol on local HGF production may be due to the accumulation of cAMP, as treatment with forskolin (30 m mmol/l) as well as 8-bromo cAMP (1 mmol/l) stimulated local HGF production (vehicle; 1.54 ± 0.19, forskolin; 12.19 ± 0.60, 8-bromo cAMP; 12.54 ± 0.38, cilostazol; 5.2 ± 0.49 ng/10 6 cells, p < 0.01 vs vehicle). Of importance, cilostazol significantly attenuated the decrease in local HGF production induced by high-d-glucose, whereas high d -glucose treatment resulted in a significant decrease in local HGF production (Fig. 5 b) . However, cilostazol treatment failed to show attenuation of local HGF production with high d -glucose treatment at 25 mmol/l. Therefore, we also studied the effect of cilostazol on growth of endothelial cells. Cilostazol stimulated growth of endothelial cells under basal conditions (Fig. 6 a) . Consistent with the previous report (Fig. 6 a) , in parallel with stimulation of local HGF production (Fig. 5 b) . Of importance, the prevention (Fig. 6 b) .
Effects of PGE 1 , PGE 2 , PGI 2 analogue and PDE 3 inhibitor on human VSMC. Since the presence of a local HGF system has also been detected in human aortic VSMC [8, 23] , we next examined the effects of prostaglandins and cilostazol on local HGF secretion from human aortic VSMC. Similar to endothelial cells, treatment with PGE 1 and PGE 2 as well as PGI 2 analogue resulted in a significant increase in local HGF secretion from VSMC in a dose-dependent manner, as shown in Figure 7 . Addition of PGI 2 analogue significantly attenuated the decrease in local HGF production induced by high d -glucose treatment. Cilostazol treatment also increased local HGF production in human VSMC (Fig. 8) . Of importance, addition of cilostazol significantly attenuated the decrease in local HGF production induced by high (Table 1) .
Discussion
HGF is a mesenchyme-derived pleiotropic factor which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis [38] [39] [40] . Moreover, we found that HGF fulfills the characteristics of an endothelium-specific growth factor [6, 7] . Therefore, we hypothesized that HGF may also have an important role in the regulation of endothelial cells. Indeed, we have previously reported that endothelial cell death induced by high d -glucose is due to decreased local HGF production in vascular cells through transforming growth factorb (TGF-b) activation [23] . This phenomenon should be important, since dysfunction of endothelial cells causing loss of multiple endothelium-derived substances (PGI 2 , nitric oxide, C-type natriurectic peptide) would result in the progression of arteriosclerotic vascular changes in diabetes [19] [20] [21] .
Therefore, we initially examined the protective action of HGF on endothelial cell injury induced by serum deprivation, which is known as a mediator of apoptosis in endothelial cells [41, 42] . Of interest, HGF could abrogate the cell death of endothelial cells mediated by serum deprivation, through the inhibition of apoptosis ( Figs. 1 and 2) . Although, currently, bFGF is only known to prevent apoptosis of endothelial cells mediated by serum deprivation [41] , HGF also has the ability to prevent apoptosis of human aortic endothelial cells induced by serum deprivation. HGF should be classed as a new member of the growth factors with anti-cell death actions in endothelial cells through the inhibition of apoptosis. The mechanisms by which HGF prevented endothelial cell death mediated by these conditions in this study are unclear. HGF is known to stimulate phosphatidylinositol-37-kinase (PI3 K), protein tyrosine phosphatase 2, phospholipase C-r, pp60 c-src , grb2/hSos1, the rho-and ras [43] [44] [45] [46] [47] [48] . The activation of these signal transduction pathways suggests that HGF will act to prevent cell death.
In this study, we next focused on the effects of PGE, PGI 2 analogue and cilostazol, which are well known to improve peripheral arterial disease in patients with diabetes [16] [17] [18] . The present study demonstrated that PGE and PGI 2 analogue as well as cilostazol treatment attenuated endothelial cell death induced by high d -glucose. Our present study cannot determine whether these agents inhibit apoptosis, resulting in an increase in cell number, or whether these agents may have no effect on apoptosis, but work primarily as a mitogen. Although the overall change in cell population may reflect a combination of the rate of cell replication and the rate of cell death, it is important to increase the overall change induced by these agents, to maintain endothelial function. More importantly, the prevention of high d -glucose-induced endothelial cell death by these drugs was abolished by addition of neutralizing antibody against HGF (Figs. 4 and 6 b) , suggesting that the protective action of PGI 2 and cilostazol on endothelial cell death is in part due to the activation of local HGF production. These results are consistent with our previous data that addition of recombinant HGF protected endothelial cells from death induced by high d -glucose [23] . Given that high d -glucose initiates apoptosis of endothelial cells [37] , increased HGF production by these agents might attenuate apoptosis of endothelial cells. This increase in local HGF production by PGE, PGI 2 analogue and cilostazol may be due to increase in cAMP. Since the promoter region of HGF gene contains a cAMP responsive element [49] , accumulation of cAMP may stimulate local HGF production probably through a cAMP responsive element. Indeed, treatment with forskolin as well as an 8-bromo cAMP analogue stimulated local HGF production.
Finally, we studied the effects of a PGI 2 analogue and cilostazol on local HGF production in VSMC. Since multiple VSMC-derived substances have profound influences on the maintenance of endothelium [4, 5] Overall, we demonstrated that treatment with PGI 2 analogue or cilostazol prevented aortic endothelial cell death induced by high d -glucose, probably through the activation of local HGF production. Increased local vascular HGF production by prostaglandins and cilostazol may prevent endothelial injury, potentially resulting in the improvement of peripheral arterial disease. 
